Currently out of the existing stock ratings of Naureen Quibria, 11 are a BUY (91.67%), 1 are a HOLD (8.33%).

Naureen Quibria

Work Performance Price Targets & Ratings Chart

Analyst Naureen Quibria, employed at CAPITAL ONE, carries an average stock price target met ratio of 16.67% that have a potential upside of 41.67% achieved within 102 days on average.

Naureen Quibria’s has documented 22 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ONCT, Oncternal Therapeutics at 04-Apr-2023.

Wall Street Analyst Naureen Quibria

Analyst best performing recommendations are on ONCT (ONCTERNAL THERAPEUTICS).
The best stock recommendation documented was for ONCT (ONCTERNAL THERAPEUTICS) at 5/10/2022. The price target of $3.5 was fulfilled within 608 days with a profit of $2.5 (250%) receiving and performance score of 4.11.
CRDF Cardiff Oncology AYLA Ayala Pharmaceuticals  ONCR Oncorus  CMRX Chimerix KZIA Kazia Therapeutics Ltd ADR ONCT Oncternal Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

14

$11.3 (418.52%)

1 months 11 days ago

0/3 (0%)

$10.54 (304.62%)

Buy

7

$4.3 (159.26%)

3 months 16 days ago

0/4 (0%)

$4.09 (140.55%)

Buy

5

$2.3 (85.19%)

6

1 years 8 months 21 days ago

1/3 (33.33%)

$3.45 (222.58%)

533

Buy

25

$23.61 (1698.56%)

2 years 9 months 8 days ago

0/1 (0%)

$18.01 (257.65%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Naureen Quibria?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?